TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33508591

Group type: EXPERIMENTAL
Intervention: Telemedicine services
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Number of subjects: 339
Study: 35318844

Group type: EXPERIMENTAL
Intervention: Mexidol intravenously, 500 mg once daily for 14 days, followed by oral Mexidol FORTE 250, 750 mg per day for 60 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mexidol treatment
Number of subjects: 70
Study: 34341325

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg for >10 min before anesthesia and during maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (control group, pumped for >10 min before anesthesia)
Number of subjects: 0
Study: 36280032

Group type: EXPERIMENTAL
Intervention: REDEFINE program utilizing health promoters (HPs) performing spirometry in primary care clinics.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 33509489

Group type: EXPERIMENTAL
Intervention: Visual cue present with rice samples (0%, 0.05%, and 0.1% MSG concentrations)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Visual cue absent with rice samples (0%, 0.05%, and 0.1% MSG concentrations)
Number of subjects: 151
Study: 35395938

Group type: EXPERIMENTAL
Intervention: Correct diagnostic suggestion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Incorrect diagnostic suggestion
Number of subjects: 44

Group type: COMPARATOR
Intervention: No diagnostic suggestion (control)
Number of subjects: 44
Study: 33451618

Group type: EXPERIMENTAL
Intervention: Enhanced counseling on optimal analgesic use
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study: 32468447

Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Humalog (Lispro)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: URLi and Humalog
Number of subjects: 80
Study: 36180905

Group type: EXPERIMENTAL
Intervention: Telehealth swallowing therapy sessions
Number of subjects: 11
Study: 34285177

Group type: EXPERIMENTAL
Intervention: Digital sports vision training program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo training procedures
Number of subjects: 32
Study: 32789932

Group type: EXPERIMENTAL
Intervention: Participants with vicarious cancer experiences
Number of subjects: 207

Group type: COMPARATOR
Intervention: Participants without vicarious cancer experiences
Number of subjects: 207
Study: 35128890

Group type: EXPERIMENTAL
Intervention: Training on T. solium taeniasis and cysticercosis control knowledge (once a year from 2016 to 2020)
Number of subjects: 663

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Baseline awareness rate of T. solium taeniasis and cysticercosis control knowledge in intervention group
Number of subjects: 663

Group type: COMPARATOR
Intervention: Baseline awareness rate of T. solium taeniasis and cysticercosis control knowledge in control group
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Comparison of awareness rates based on education levels
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Comparison of awareness rates based on duration of working experiences
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Comparison of awareness rates among medical professionals with different education levels in intervention group
Number of subjects: 663
Study: 33293312

Group type: EXPERIMENTAL
Intervention: OPASS programme
Number of subjects: 210

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 210
Study: 36364919

Group type: EXPERIMENTAL
Intervention: LabinicTM (multi-strain probiotic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32458282

Group type: EXPERIMENTAL
Intervention: TBR NFT (Theta/Beta Ratio Neurofeedback Training)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham NFT
Number of subjects: 12
Study: 35259027

Group type: EXPERIMENTAL
Intervention: Caregiver-reported PedsQL score
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Child-reported PedsQL score
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Agreement between caregiver and child total PedsQL scores
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Factors associated with differences between caregiver and child report
Number of subjects: 309
Study: 33677624

Group type: EXPERIMENTAL
Intervention: Transection of POL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Transection of dMCL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined torque contributions of dMCL and POL
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intact state
Number of subjects: 8
Study: 33071986

Group type: EXPERIMENTAL
Intervention: Gushen'antai pills (GSATP) 6 g, tid for 12 weeks
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Gushen'antai pills (GSATP) 6 g, tid for 12 weeks (younger than 35 years)
Number of subjects: 271
Study: 35789604

Group type: EXPERIMENTAL
Intervention: Sanfeng Tongqiao Diwan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tongqiao Biyan Pian
Number of subjects: 0
Study: 32667155

Group type: EXPERIMENTAL
Intervention: Muscular tissue oxygen saturation‐guided care (n = 400)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care (n = 399)
Number of subjects: 800
Study: 34590286

Group type: EXPERIMENTAL
Intervention: Unsupervised statistical monitoring using mixed‐effects statistical models
Number of subjects: 0
Study: 33081983

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support to reach caloric and protein goals
Number of subjects: 378

Group type: COMPARATOR
Intervention: Standard hospital food
Number of subjects: 378
Study: 32227755

Group type: EXPERIMENTAL
Intervention: Initial invasive strategy (angiography and revascularization when feasible) plus medical therapy
Number of subjects: 5179

Group type: COMPARATOR
Intervention: Initial conservative strategy (medical therapy alone and angiography if medical therapy failed)
Number of subjects: 5179

Group type: EXPERIMENTAL
Intervention: Initial invasive strategy
Number of subjects: 5179

Group type: COMPARATOR
Intervention: Initial conservative strategy
Number of subjects: 5179

Group type: EXPERIMENTAL
Intervention: Key secondary outcome
Number of subjects: 5179
Study: 35945651

Group type: EXPERIMENTAL
Intervention: 5 raw eggs (∼30 g protein)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 boiled eggs (∼30 g protein)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control breakfast (∼5 g protein)
Number of subjects: 45
Study: 33962515

Group type: EXPERIMENTAL
Intervention: Education plus therapeutic alliance
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 222

Group type: COMPARATOR
Intervention: No education
Number of subjects: 222
Study: 32560714

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including workstation ergonomics, health promotion information group workshops, neck exercises, and an adherence app for 12 weeks.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 120
Study: 32843262

Group type: EXPERIMENTAL
Intervention: Empowerment-based intervention
Number of subjects: 85
Study: 35288105

Group type: EXPERIMENTAL
Intervention: Diamondback 360 Coronary Orbital Atherectomy System
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 2000
Study: 36257950

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 181
Study: 33626028

Group type: EXPERIMENTAL
Intervention: Postoperative hypotension (POH) defined as a single MAP measurement below thresholds of ≤75, ≤65, and ≤55 mm Hg.
Number of subjects: 67968

Group type: EXPERIMENTAL
Intervention: Postoperative hypotension (POH) with intraoperative hypotension (IOH) defined as intraoperative MAP ≤65 mm Hg.
Number of subjects: 67968

Group type: COMPARATOR
Intervention: Postoperative hypotension (POH) without intraoperative hypotension (IOH).
Number of subjects: 67968
Study: 35126939

Group type: EXPERIMENTAL
Intervention: Ultrapulse CO2 lattice laser combined with PRP and Yifu
Number of subjects: 700

Group type: COMPARATOR
Intervention: Ultrapulse CO2 lattice laser
Number of subjects: 700
Study: 34959931

Group type: EXPERIMENTAL
Intervention: High Protein Diet (HP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mediterranean Diet (M)
Number of subjects: 20
Study: 34342814

Group type: EXPERIMENTAL
Intervention: Business letter invitation (n=360)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Greeting card invitation (n=348)
Number of subjects: 708
Study: 33450071

Group type: EXPERIMENTAL
Intervention: Baseline dual‐energy X‐ray absorptiometry (DXA) appendicular lean mass (ALM) adjusted for height2
Number of subjects: 11187
Study: 33901511

Group type: EXPERIMENTAL
Intervention: Pursuit eye movements immediately after fear memory reactivation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pursuit eye movements 10 min after fear memory reactivation
Number of subjects: 38
Study: 34262052

Group type: EXPERIMENTAL
Intervention: Microneedle patches (MNPs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intramuscular (IM) route
Number of subjects: 22
Study: 36138087

Group type: EXPERIMENTAL
Intervention: Icodextrin (ICO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glucose (GLU)
Number of subjects: 22
Study: 34616361

Group type: EXPERIMENTAL
Intervention: 25 mg imigliptin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 50 mg imigliptin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 25 mg alogliptin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 32160268

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 0
Study: 36372282

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (oil blend), applied once a day for 15 minutes over 3 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 33449819

Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention over four weeks for least regular sleepers (N = 22, SRI ≤ 81.4)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Change in CATS Time during the intervention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CATS Benefits
Number of subjects: 45
Study: 33499438

Group type: EXPERIMENTAL
Intervention: cd‐HA‐gelatin (medium or low molecular weight)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: cd‐HA‐gelatin (high molecular weight)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 48
Study: 35219277

Group type: EXPERIMENTAL
Intervention: Sarilumab 400 mg
Number of subjects: 1822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1822

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 1822
Study: 33287626

Group type: EXPERIMENTAL
Intervention: Genetically predicted levels of very small and small very low-density lipoprotein, intermediate-density lipoprotein, and large low-density lipoprotein
Number of subjects: 3279

Group type: EXPERIMENTAL
Intervention: Genetically predicted diastolic blood pressure
Number of subjects: 3279

Group type: EXPERIMENTAL
Intervention: Genetically predicted systolic blood pressure
Number of subjects: 3279
Study: 34632933

Group type: EXPERIMENTAL
Intervention: 120 mg/day standardized cranberry extract
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 240 mg/day standardized cranberry extract
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard management (SM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nitrofurantoin administration
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Standardized cranberry extract
Number of subjects: 64
Study: 33987685

Group type: EXPERIMENTAL
Intervention: European Childhood Obesity Risk Evaluation (CORE) index
Number of subjects: 2775
Study: 32986391

Group type: EXPERIMENTAL
Intervention: Plyometric drop jump training (PJT-early)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Plyometric drop jump training (PJT-late)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Active soccer-control group (CG-early)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Active soccer-control group (CG-late)
Number of subjects: 76
Study: 35990584

Group type: EXPERIMENTAL
Intervention: PrEP delivery integrated into ART clinics
Number of subjects: 1381

Group type: COMPARATOR
Intervention: ART for partners living with HIV
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: ART for partners living with HIV after PrEP launch
Number of subjects: 1381

Group type: COMPARATOR
Intervention: ART for partners living with HIV before PrEP launch
Number of subjects: 1381
Study: 34907082

Group type: EXPERIMENTAL
Intervention: Ipatasertib plus Paclitaxel
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo plus Paclitaxel
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Ipatasertib treatment
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: High baseline pAKT levels
Number of subjects: 151
Study: 32464485

Group type: EXPERIMENTAL
Intervention: Mock interviews with trained actors as a training tool for child interviewing
Number of subjects: 35
Study: 35133064

Group type: COMPARATOR
Intervention: Imatinib mesylate 0.1% (single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Imatinib mesylate 0.1% (multiple doses, once daily for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Imatinib mesylate 0.3% (single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Imatinib mesylate 0.3% (multiple doses, once daily for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo (single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo (multiple doses, once daily for 7 days)
Number of subjects: 16
Study: 34180949

Group type: EXPERIMENTAL
Intervention: Home health postoperative DBS management
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 44
Study: 35184004

Group type: EXPERIMENTAL
Intervention: Alcohol liking
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Greater alcohol liking and wanting
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Greater alcohol sedation
Number of subjects: 294
Study: 33222455

Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (EIN)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enteral nutrition (EN)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enteral immunonutrition (EIN) and Enteral nutrition (EN)
Number of subjects: 120
Study: 616497045

Group type: EXPERIMENTAL
Intervention: Eggshell calcium (300 mg/d)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (300 mg/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (no calcium supplementation)
Number of subjects: 54
Study: 35115339

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 µg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Budesonide/formoterol 200/6 µg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 39
Study: 33657675

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study: 33724254

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg/day) plus pentoxifylline (400 mg three times daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sertraline (100 mg/day) plus placebo
Number of subjects: 56
Study: 32909815

Group type: EXPERIMENTAL
Intervention: D-NAM appliance
Number of subjects: 34

Group type: COMPARATOR
Intervention: No-treatment (control)
Number of subjects: 34
Study: 35834107

Group type: EXPERIMENTAL
Intervention: Diabetes-specific nutritional supplement (DSNS) plus standard of care (SOC)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 171
Study: 34629370

Group type: EXPERIMENTAL
Intervention: Moderate job strain
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High job strain
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Effort-reward imbalance
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High overcommitment
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Moderate exposure to musculoskeletal pain/injury
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High exposure to musculoskeletal pain/injury
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Degree level education
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Elementary/high school level education
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Age 31-40 years
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Age ≥41 years
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Age >40 years
Number of subjects: 158
Study: 33256753

Group type: EXPERIMENTAL
Intervention: Physical activity coaching intervention (education session + five 20-min telephone sessions)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physical activity coaching intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (education session only)
Number of subjects: 120
Study: 35736783

Group type: EXPERIMENTAL
Intervention: Communication intervention (2.5-minute video, 3-page brief questionnaire, wallet card with question prompts)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Communication intervention
Number of subjects: 53
Study: 33671220

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 75 mg/kg body weight daily for 14 days
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 225
Study: 32370780

Group type: EXPERIMENTAL
Intervention: Preemptive local infiltration with betamethasone and ropivacaine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 116
Study: 34740596

Group type: EXPERIMENTAL
Intervention: COMPASS‐TC (comprehensive transitional care model)
Number of subjects: 2262

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2262
Study: 35293153

Group type: EXPERIMENTAL
Intervention: HFNCO (2 L/kg/min)
Number of subjects: 87
Study: 33864153

Group type: EXPERIMENTAL
Intervention: Fosfomycin-trometamol treatment for ASB (77 patients)
Number of subjects: 594

Group type: COMPARATOR
Intervention: No intervention (75 patients)
Number of subjects: 594
Study: 35695234

Group type: EXPERIMENTAL
Intervention: Personalized telephone coaching (average of 13 sessions, 48 minutes each over 6 months)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Personalized telephone coaching
Number of subjects: 314

Group type: COMPARATOR
Intervention: TAU+
Number of subjects: 314
Study: 34384540

Group type: EXPERIMENTAL
Intervention: Vi‐tetanus toxoid conjugate vaccine (Vi‐TT)
Number of subjects: 41344

Group type: COMPARATOR
Intervention: SA 14‐14‐2 Japanese encephalitis (JE) vaccine
Number of subjects: 41344
Study: 32799667

Group type: EXPERIMENTAL
Intervention: Electronic headache diary (daily assessment of headache presence and severity)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Recall questionnaire (retrospective estimation of headache days on a monthly basis)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Headaches lasting 8 hours or more
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe headaches
Number of subjects: 182
Study: 33927110

Group type: EXPERIMENTAL
Intervention: 100% O2 (hyperoxic setting [HS])
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hypoxic air (nonhyperoxic setting [NHS])
Number of subjects: 15
Study: 33139234

Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip tube (PFT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Portex tube (PTT)
Number of subjects: 40
Study: 35440935

Group type: EXPERIMENTAL
Intervention: Coriander seed oil (CSO) 200 mg daily for 28 days
Number of subjects: 0
Study: 32341106

Group type: EXPERIMENTAL
Intervention: PDE4 inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 33423550

Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 820
Study: 32692755

Group type: EXPERIMENTAL
Intervention: Heart rate-reducing genetic variant at the HCN4 locus encoding ivabradine's drug target
Number of subjects: 0
Study: 36254140

Group type: EXPERIMENTAL
Intervention: Catheter balloon dilation combined with cold fluid compensatory swallowing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Catheter balloon dilation
Number of subjects: 0
Study: 33445213

Group type: EXPERIMENTAL
Intervention: Astaxanthin (AST) supplementation, 8 mg/d for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 32330107

Group type: EXPERIMENTAL
Intervention: KCA (7g BHB, 100mg caffeine, amino acids)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water (control condition)
Number of subjects: 24
Study: 34431993

Group type: EXPERIMENTAL
Intervention: Type 1 myocardial infarction
Number of subjects: 48282

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction
Number of subjects: 48282

Group type: EXPERIMENTAL
Intervention: Risk factors for type 1 and type 2 myocardial infarction
Number of subjects: 48282

Group type: EXPERIMENTAL
Intervention: Prior history of type 2 events
Number of subjects: 48282

Group type: EXPERIMENTAL
Intervention: Sex as a predictor
Number of subjects: 48282
Study: 33536283

Group type: EXPERIMENTAL
Intervention: Isoniazid, pyrazinamide, rifampicin, moxifloxacin (individual and in combination)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Isoniazid and pyrazinamide (combination)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET/CT imaging
Number of subjects: 160
Study: 34605947

Group type: EXPERIMENTAL
Intervention: Adrecizumab (2 or 4 mg/kg b.w.)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 616388368

Group type: EXPERIMENTAL
Intervention: Predictive nursing intervention measures plus conventional nursing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 120
Study: 36881396

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562